Literature DB >> 20419833

Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells.

Elisabeth Emonds1, Brit Fitzner, Robert Jaster.   

Abstract

AIM: To gain molecular insights into the action of the histone deacetylase inhibitor (HDACI) trichostatin-A (TSA) in pancreatic cancer (PC) cells.
METHODS: Three PC cell lines, BxPC-3, AsPC-1 and CAPAN-1, were treated with various concentrations of TSA for defined periods of time. DNA synthesis was assessed by measuring the incorporation of 5-bromo-2'-deoxyuridine. Gene expression at the level of mRNA was quantified by real-time polymerase chain reaction. Expression and phosphorylation of proteins was monitored by immunoblotting, applying an infrared imaging technology. To study the role of p38 MAP kinase, the specific enzyme inhibitor SB202190 and an inactive control substance, SB202474, were employed.
RESULTS: TSA most efficiently inhibited BrdU incorporation in BxPC-3 cells, while CAPAN-1 cells displayed the lowest and AsPC-1 cells an intermediate sensitivity. The biological response of the cell lines correlated with the increase of histone H3 acetylation after TSA application. In BxPC-3 cells (which are wild-type for KRAS), TSA strongly inhibited phosphorylation of ERK 1/2 and AKT. In contrast, activities of ERK and AKT in AsPC-1 and CAPAN-1 cells (both expressing oncogenic KRAS) were not or were only modestly affected by TSA treatment. In all three cell lines, but most pronounced in BxPC-3 cells, TSA exposure induced an activation of the MAP kinase p38. Inhibition of p38 by SB202190 slightly but significantly diminished the antiproliferative effect of TSA in BxPC-3 cells. Interestingly, only BxPC-3 cells responded to TSA treatment by a significant increase of the mRNA levels of bax, a pro-apoptotic member of the BCL gene family. Finally, in BxPC-3 and AsPC-1 cells, but not in the cell line CAPAN-1, significantly higher levels of the cell cycle inhibitor protein p21(Waf1) were observed after TSA application.
CONCLUSION: The biological effect of TSA in PC cells correlates with the increase of acetyl-H3, p21(Waf1), phospho-p38 and bax levels, and the decrease of phospho-ERK 1/2 and phospho-AKT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419833      PMCID: PMC2860073          DOI: 10.3748/wjg.v16.i16.1970

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.

Authors:  Susanne Gahr; Matthias Ocker; Marion Ganslmayer; Steffen Zopf; Kinya Okamoto; Andrea Hartl; Sandra Leitner; Eckhart G Hahn; Christoph Herold
Journal:  Int J Oncol       Date:  2007-09       Impact factor: 5.650

Review 2.  Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.

Authors:  C A Hassig; S L Schreiber
Journal:  Curr Opin Chem Biol       Date:  1997-10       Impact factor: 8.822

Review 3.  Pancreatic cancer: a review of recent advances.

Authors:  Florian Eckel; Günter Schneider; Roland M Schmid
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

4.  Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.

Authors:  Norihiro Sato; Hiroyuki Matsubayashi; Tadayoshi Abe; Noriyoshi Fukushima; Michael Goggins
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

5.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

Authors:  Paolo Piacentini; Massimo Donadelli; Chiara Costanzo; Patrick S Moore; Marta Palmieri; Aldo Scarpa
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

6.  Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.

Authors:  Beobyi Lee; Cheorl-Ho Kim; Sung-Kwon Moon
Journal:  FEBS Lett       Date:  2006-09-05       Impact factor: 4.124

7.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

Review 8.  PI3K/PTEN signaling in angiogenesis and tumorigenesis.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

9.  Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.

Authors:  Jiro Okami; Diane M Simeone; Craig D Logsdon
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells.

Authors:  Anika Jonitz; Brit Fitzner; Robert Jaster
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

View more
  4 in total

Review 1.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

2.  The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.

Authors:  Ravi P Sahu; Sanjay Batra; Prabodh K Kandala; Thomas L Brown; Sanjay K Srivastava
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-17       Impact factor: 3.333

3.  EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.

Authors:  Desamparados Roda; Josefa Castillo; Marcelino Telechea-Fernández; Anabel Gil; Gerardo López-Rodas; Luís Franco; Patricia González-Rodríguez; Susana Roselló; J Alejandro Pérez-Fidalgo; Elena R García-Trevijano; Andrés Cervantes; Rosa Zaragozá
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

4.  HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells.

Authors:  Atiye Seda Yar Saglam; Akin Yilmaz; Hacer Ilke Onen; Ebru Alp; Handan Kayhan; Abdullah Ekmekci
Journal:  EXCLI J       Date:  2016-04-04       Impact factor: 4.068

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.